Alveolar cytokines and interferon autoantibodies in COVID-19 ARDS
BackgroundType I interferon (IFN-I) and IFN autoantibodies play a crucial role in controlling SARS-CoV-2 infection. The levels of these mediators have only rarely been studied in the alveolar compartment in patients with COVID-19 acute respiratory distress syndrome (CARDS) but have not been compared...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-03-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1353012/full |
| _version_ | 1797256473349193728 |
|---|---|
| author | Trine B. Jonassen Sofie E. Jørgensen Sofie E. Jørgensen Nikki H. Mitchell Trine H. Mogensen Trine H. Mogensen Ronan M. G. Berg Ronan M. G. Berg Ronan M. G. Berg Ronan M. G. Berg Andreas Ronit Ronni R. Plovsing Ronni R. Plovsing |
| author_facet | Trine B. Jonassen Sofie E. Jørgensen Sofie E. Jørgensen Nikki H. Mitchell Trine H. Mogensen Trine H. Mogensen Ronan M. G. Berg Ronan M. G. Berg Ronan M. G. Berg Ronan M. G. Berg Andreas Ronit Ronni R. Plovsing Ronni R. Plovsing |
| author_sort | Trine B. Jonassen |
| collection | DOAJ |
| description | BackgroundType I interferon (IFN-I) and IFN autoantibodies play a crucial role in controlling SARS-CoV-2 infection. The levels of these mediators have only rarely been studied in the alveolar compartment in patients with COVID-19 acute respiratory distress syndrome (CARDS) but have not been compared across different ARDS etiologies, and the potential effect of dexamethasone (DXM) on these mediators is not known.MethodsWe assessed the integrity of the alveolo-capillary membrane, interleukins, type I, II, and III IFNs, and IFN autoantibodies by studying the epithelial lining fluid (ELF) volumes, alveolar concentration of protein, and ELF-corrected concentrations of cytokines in two patient subgroups and controls.ResultsA total of 16 patients with CARDS (four without and 12 with DXM treatment), eight with non-CARDS, and 15 healthy controls were included. The highest ELF volumes and protein levels were observed in CARDS. Systemic and ELF-corrected alveolar concentrations of interleukin (IL)-6 appeared to be particularly low in patients with CARDS receiving DXM, whereas alveolar levels of IL-8 were high regardless of DXM treatment. Alveolar levels of IFNs were similar between CARDS and non-CARDS patients, and IFNα and IFNω autoantibody levels were higher in patients with CARDS and non-CARDS than in healthy controls.ConclusionsPatients with CARDS exhibited greater alveolo-capillary barrier disruption with compartmentalization of IL-8, regardless of DXM treatment, whereas systemic and alveolar levels of IL-6 were lower in the DXM-treated subgroup. IFN-I autoantibodies were higher in the BALF of CARDS patients, independent of DXM, whereas IFN autoantibodies in plasma were similar to those in controls. |
| first_indexed | 2024-04-24T22:22:18Z |
| format | Article |
| id | doaj.art-3a3e4f0b1b104fadb745d22c39b97d3e |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-24T22:22:18Z |
| publishDate | 2024-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-3a3e4f0b1b104fadb745d22c39b97d3e2024-03-20T05:13:08ZengFrontiers Media S.A.Frontiers in Immunology1664-32242024-03-011510.3389/fimmu.2024.13530121353012Alveolar cytokines and interferon autoantibodies in COVID-19 ARDSTrine B. Jonassen0Sofie E. Jørgensen1Sofie E. Jørgensen2Nikki H. Mitchell3Trine H. Mogensen4Trine H. Mogensen5Ronan M. G. Berg6Ronan M. G. Berg7Ronan M. G. Berg8Ronan M. G. Berg9Andreas Ronit10Ronni R. Plovsing11Ronni R. Plovsing12Department of Anesthesiology and Intensive Care, Copenhagen University Hospital-Amager and Hvidovre Hospitals, Hvidovre, DenmarkDepartment of Infectious Diseases, Aarhus University Hospital (AUH), Aarhus, DenmarkDepartment of Biomedicine, Aarhus University, Aarhus, DenmarkDepartment of Clinical Biochemistry, Copenhagen University Hospital-Amager and Hvidovre, Hvidovre, DenmarkDepartment of Infectious Diseases, Aarhus University Hospital (AUH), Aarhus, DenmarkDepartment of Biomedicine, Aarhus University, Aarhus, DenmarkDepartment of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DenmarkDepartment of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital-Rigshospitalet, Copenhagen, DenmarkCentre for Physical Activity Research, Copenhagen University Hospital-Rigshospitalet, Copenhagen, DenmarkNeurovascular Research Laboratory, Faculty of Life Sciences and Education, University of South Wales, Pontypridd, United KingdomDepartment of Infectious Diseases, Copenhagen University Hospital-Amager and Hvidovre Hospitals, Hvidovre, DenmarkDepartment of Anesthesiology and Intensive Care, Copenhagen University Hospital-Amager and Hvidovre Hospitals, Hvidovre, Denmark0Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DenmarkBackgroundType I interferon (IFN-I) and IFN autoantibodies play a crucial role in controlling SARS-CoV-2 infection. The levels of these mediators have only rarely been studied in the alveolar compartment in patients with COVID-19 acute respiratory distress syndrome (CARDS) but have not been compared across different ARDS etiologies, and the potential effect of dexamethasone (DXM) on these mediators is not known.MethodsWe assessed the integrity of the alveolo-capillary membrane, interleukins, type I, II, and III IFNs, and IFN autoantibodies by studying the epithelial lining fluid (ELF) volumes, alveolar concentration of protein, and ELF-corrected concentrations of cytokines in two patient subgroups and controls.ResultsA total of 16 patients with CARDS (four without and 12 with DXM treatment), eight with non-CARDS, and 15 healthy controls were included. The highest ELF volumes and protein levels were observed in CARDS. Systemic and ELF-corrected alveolar concentrations of interleukin (IL)-6 appeared to be particularly low in patients with CARDS receiving DXM, whereas alveolar levels of IL-8 were high regardless of DXM treatment. Alveolar levels of IFNs were similar between CARDS and non-CARDS patients, and IFNα and IFNω autoantibody levels were higher in patients with CARDS and non-CARDS than in healthy controls.ConclusionsPatients with CARDS exhibited greater alveolo-capillary barrier disruption with compartmentalization of IL-8, regardless of DXM treatment, whereas systemic and alveolar levels of IL-6 were lower in the DXM-treated subgroup. IFN-I autoantibodies were higher in the BALF of CARDS patients, independent of DXM, whereas IFN autoantibodies in plasma were similar to those in controls.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1353012/fullbronchoalveolar lavage fluidcoronavirus disease 2019interferonsinflammationacute respiratory distress syndromeautoantibodies |
| spellingShingle | Trine B. Jonassen Sofie E. Jørgensen Sofie E. Jørgensen Nikki H. Mitchell Trine H. Mogensen Trine H. Mogensen Ronan M. G. Berg Ronan M. G. Berg Ronan M. G. Berg Ronan M. G. Berg Andreas Ronit Ronni R. Plovsing Ronni R. Plovsing Alveolar cytokines and interferon autoantibodies in COVID-19 ARDS Frontiers in Immunology bronchoalveolar lavage fluid coronavirus disease 2019 interferons inflammation acute respiratory distress syndrome autoantibodies |
| title | Alveolar cytokines and interferon autoantibodies in COVID-19 ARDS |
| title_full | Alveolar cytokines and interferon autoantibodies in COVID-19 ARDS |
| title_fullStr | Alveolar cytokines and interferon autoantibodies in COVID-19 ARDS |
| title_full_unstemmed | Alveolar cytokines and interferon autoantibodies in COVID-19 ARDS |
| title_short | Alveolar cytokines and interferon autoantibodies in COVID-19 ARDS |
| title_sort | alveolar cytokines and interferon autoantibodies in covid 19 ards |
| topic | bronchoalveolar lavage fluid coronavirus disease 2019 interferons inflammation acute respiratory distress syndrome autoantibodies |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1353012/full |
| work_keys_str_mv | AT trinebjonassen alveolarcytokinesandinterferonautoantibodiesincovid19ards AT sofieejørgensen alveolarcytokinesandinterferonautoantibodiesincovid19ards AT sofieejørgensen alveolarcytokinesandinterferonautoantibodiesincovid19ards AT nikkihmitchell alveolarcytokinesandinterferonautoantibodiesincovid19ards AT trinehmogensen alveolarcytokinesandinterferonautoantibodiesincovid19ards AT trinehmogensen alveolarcytokinesandinterferonautoantibodiesincovid19ards AT ronanmgberg alveolarcytokinesandinterferonautoantibodiesincovid19ards AT ronanmgberg alveolarcytokinesandinterferonautoantibodiesincovid19ards AT ronanmgberg alveolarcytokinesandinterferonautoantibodiesincovid19ards AT ronanmgberg alveolarcytokinesandinterferonautoantibodiesincovid19ards AT andreasronit alveolarcytokinesandinterferonautoantibodiesincovid19ards AT ronnirplovsing alveolarcytokinesandinterferonautoantibodiesincovid19ards AT ronnirplovsing alveolarcytokinesandinterferonautoantibodiesincovid19ards |